Overview
MariMed Q3 revenue misses analyst expectations, adjusted EBITDA also missed estimates
Company reports sequential growth in wholesale and retail revenues for Q3
MariMed expands brand distribution to Maine, Pennsylvania, and New York
Outlook
Company anticipates distribution in Pennsylvania and New York to begin in 2026
MariMed plans to launch hemp-derived THC products in Rhode Island by early 2026
Result Drivers
WHOLESALE EXPANSION - Sequential growth in wholesale revenues driven by expansion in Massachusetts and Illinois
NEW MARKET ENTRY - Expansion into Maine, Pennsylvania, and New York as part of strategic growth plan
COST MANAGEMENT - Improved profitability through disciplined cost management and operational efficiencies
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $40.80 mln | $42.40 mln (3 Analysts) |
Q3 Adjusted Net loss | Slight Miss* | -$1.50 mln | -$1.49 mln (2 Analysts) |
Q3 GAAP Net loss | -$2.90 mln | ||
Q3 Adjusted EBITDA | Miss | $5.10 mln | $5.89 mln (3 Analysts) |
Q3 Gross Margin | 40.00% | ||
Q3 Adjusted EBITDA Margin | 13.00% | ||
Q3 Adjusted Gross Margin | 41.00% |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for MariMed Inc is $0.23, about 53.8% above its November 4 closing price of $0.10
Press Release: ID:nGNX8Ytv7s
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)